Works matching IS 2160763X AND DT 2016 AND VI 5 AND IP 4

Results: 10

A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy.

Published in:

Clinical Pharmacology in Drug Development, 2016, v. 5, n. 4, p. 259, doi. 10.1002/cpdd.237

By:

Zhang, Wenhui;
Kernstock, Robert M.;
Karrer, Erik E.;
Cohen, Stanley B.;
Chindalore, Vishala L.;
Kivitz, Alan J.;
Blahunka, Paul C.;
Delgado‐Herrera, Leticia;
Zeiher, Bernhardt G.;
Samberg, Nancy L.;
Garg, Jay P.

Publication type:

Article

Phase IA Clinical Trial Evaluating the Tolerability, Pharmacokinetics, and Analgesic Efficacy of an Intrathecally Administered Neurotensin A Analogue in Central Neuropathic Pain Following Spinal Cord Injury.

Published in:

Clinical Pharmacology in Drug Development, 2016, v. 5, n. 4, p. 250, doi. 10.1002/cpdd.253

By:

Sang, Christine N.;
Barnabe, Kate J.;
Kern, Steven E.

Publication type:

Article

Issue Information.

Published in:: Clinical Pharmacology in Drug Development, 2016, v. 5, n. 4, p. 241, doi. 10.1002/cpdd.227
Publication type:: Article

Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation.

Published in:

Clinical Pharmacology in Drug Development, 2016, v. 5, n. 4, p. 296, doi. 10.1002/cpdd.240

By:

Weetall, Marla;
Davis, Thomas;
Elfring, Gary;
Northcutt, Valerie;
Cao, Liangxian;
Moon, Young‐Choon;
Riebling, Peter;
Dali, Mandar;
Hirawat, Samit;
Babiak, John;
Colacino, Joseph;
Almstead, Neil;
Spiegel, Robert;
Peltz, Stuart W.

Publication type:

Article

Compelling Relationship of CYP3A Induction to Levels of the Putative Biomarker 4β-Hydroxycholesterol and Changes in Midazolam Exposure.

Published in:

Clinical Pharmacology in Drug Development, 2016, v. 5, n. 4, p. 245, doi. 10.1002/cpdd.265

By:

Mangold, James B.;
Wu, Fan;
Rebello, Sam

Publication type:

Article

A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease.

Published in:

Clinical Pharmacology in Drug Development, 2016, v. 5, n. 4, p. 314, doi. 10.1002/cpdd.241

By:

Sabounjian, LuAnn;
Graham, Philip;
Wu, Lijun;
Braman, Virginia;
Cheng, Changfu;
Liu, Julie;
Shipley, James;
Neutel, Joel;
Dao, Michael

Publication type:

Article

Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2016, v. 5, n. 4, p. 306, doi. 10.1002/cpdd.244

By:

Erpenbeck, Veit J.;
Vets, Eva;
Gheyle, Lien;
Osuntokun, Wande;
Larbig, Michael;
Neelakantham, Srikanth;
Sandham, David;
Dubois, Gerald;
Elbast, Walid;
Goldsmith, Paul;
Weiss, Markus

Publication type:

Article

A Pharmacokinetic Study Comparing Eslicarbazepine Acetate Administered Orally as a Crushed or Intact Tablet in Healthy Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2016, v. 5, n. 4, p. 278, doi. 10.1002/cpdd.242

By:

Sunkaraneni, Soujanya;
Kharidia, Jahnavi;
Schutz, Ralph;
Blum, David;
Cheng, Hailong

Publication type:

Article

Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2016, v. 5, n. 4, p. 285, doi. 10.1002/cpdd.245

By:

Vaidya, Soniya S.;
Khindri, Sanjeev;
Maahs, Suzanne;
Machineni, Surendra;
Hara, Hisanori;
Juan, Axel;
Kaiser, Günther

Publication type:

Article

Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.

Published in:

Clinical Pharmacology in Drug Development, 2016, v. 5, n. 4, p. 269, doi. 10.1002/cpdd.246

By:

Polepally, Akshanth R.;
Dutta, Sandeep;
Hu, Beibei;
Podsadecki, Thomas J.;
Awni, Walid M.;
Menon, Rajeev M.

Publication type:

Article